Q-omics provides the consensus-scored CCDC179 profile across patient tissues and cancer cell-line models. CCDC179 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CCDC179 is differentially expressed in 4, with the highest sampling consensus in BLCA. Additionally, CCDC179 RNA expression shows 8,371 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight UVM, BLCA, and LAML as cancer lineages where CCDC179 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC179 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC179 survival associations across molecular data types. CCDC179 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC179 RNA expression–survival associations across cancer types. High CCDC179 expression shows unfavorable associations in UVM, LUSC, DLBC, LIHC and THCA, but favorable associations in SCLC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CCDC179 RNA expression.
This table summarizes CCDC179 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC179. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC179 shows lower tumor expression in PAAD and higher tumor expression in BLCA, BRCA and PRAD. The BLCA box plot shows higher CCDC179 RNA expression in tumor versus normal tissue (log2 FC = +0.067, t-test p = .019).
This table shows molecular features associated with CCDC179 in patient tissues and cancer cell lines. In patient samples, CCDC179 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC179 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BREAST.
